What did Evercore change in the EWTX analyst rating on February 26, 2026

Evercore ISI maintained an Outperform rating on **EWTX** and raised its price target to **$45** on **February 26, 2026**, signaling stronger conviction in Edgewise’s longer-term value.

Did Raymond James change its view in the latest EWTX analyst rating

Raymond James maintained a **Strong Buy** on **EWTX** on **February 26, 2026**, calling the long-term risk/reward skew attractive and keeping its positive stance unchanged.

How should investors use the latest EWTX analyst rating updates

Investors should treat the ratings as informed opinions that add context to company fundamentals, pipeline milestones, and market signals. Combine these views with financial analysis and your risk tolerance.

Where can I read the analyst notes cited in this EWTX analyst rating report

The analyst summaries are available on StreetInsider. See the Evercore and Raymond James notes linked in this article for primary source details and exact wording.

Analyst Ratings

Evercore Maintains Outperform, PT $45 for Edgewise Therapeutics (EWTX) Feb 2026

ByHuzaifa Zahoor February 28, 2026

On February 26, 2026 Evercore ISI maintained Outperform on Edgewise Therapeutics, Inc. and raised its price target to $45, the headline move in the latest EWTX analyst rating updates. The same day Raymond James kept a Strong Buy rating, calling the long-term risk/reward skew attractive. We track both actions because they reinforce positive analyst conviction while leaving near-term share reaction muted. For more on the filings see the Evercore and Raymond James notes on StreetInsider and our EWTX coverage on Meyka AI